Investing in Vaccine Security in the ASEAN Region
Vaccine security and self-sufficiency have received increased global attention in the wake of the COVID-19 pandemic, as low- and middle-income countries were heavily dependent on high-income countries (HICs) and international organizations for vaccine supply, resulting in global competition for vacc...
Gespeichert in:
Hauptverfasser: | , , , , , , , |
---|---|
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Vaccine security and self-sufficiency
have received increased global attention in the wake of the
COVID-19 pandemic, as low- and middle-income countries were
heavily dependent on high-income countries (HICs) and
international organizations for vaccine supply, resulting in
global competition for vaccines and huge inequities.
Achieving vaccine security and self-sufficiency is of high
importance to Southeast Asia. To achieve this goal, the
Association of Southeast Asian Nations (ASEAN) established
the ASEAN vaccine security and self-reliance (AVSSR)
initiative. Building on the efforts of ASEAN leadership, the
World Bank commissioned this study to estimate the public
health and economic benefits arising from investments in
AVSSR, specifically in vaccine research and development
(R&D), manufacturing, and regulation. The study assumes
that five ASEAN countries - Indonesia, Malaysia, the
Philippines, Thailand, and Vietnam - make public and private
investments to strengthen vaccine security. Applying a
societal perspective, the study considers four different
investments scenarios. Scenario 1 assumes that costs will be
shared between these five countries and that these countries
alone will benefit from the vaccine security efforts, while
Scenario 2 assumes health and economic benefits to the other
five ASEAN countries (Brunei, Cambodia, Laos, Myanmar, and
Singapore) as well. Scenario 3 assumes that only one country
of 100 million people produces and prioritizes vaccines for
its population, while Scenario 4 assumes a pandemic of
COVID19 magnitude. The findings of the study clearly show
that regional investments in clinical trials, manufacturing
and regulatory capacity building will have a substantial
public health impact and offer high benefit-cost ratios.
Findings from this study align with the AVSSR Strategic and
Action Plan 2021-2025, which makes the case for stronger
regional vaccine capacity, enhanced vaccine manufacturing
capacity, and human resource development to realize the goal
of self-reliance. |
---|